Now Available: Diagnostics Year in Review 2023. Click to Download Report.
Rebus Biosystems, Inc., a life science technology company building innovative tools to enable spatial omics without compromise, today announced the closing of a $20 million Series B financing round, led by Illumina Ventures...“We are excited to support Rebus Biosystems’ mission to bring powerful new spatial omics tools and assays to market,” said Tom Willis, Partner at Illumina Ventures. “The a...
Cell therapy and technologies company SQZ Biotechnologies began trading on the NYSE today. Armon Sharei, CEO of SQZ Biotechnologies, joins Yahoo Finance's Zack Guzman and Anjalee Khemlani to discuss.
The Endpoints 11: Here are some of the most promising startups in biotech. And Covid-19 isn't going to stop them..."The idea driving Encoded’s team revolves around the destructive role that mutations in the SCN1A gene have on GABAergic neurons, which in turn are a likely driver of SCN1A-positive Dravet syndrome."
Pattern Bioscience, Inc. announced $9M in additional funding to accelerate the development and clinical validation of its Digital CultureTM rapid bacterial identification and susceptibility testing (ID/AST) technology. Illumina Ventures led the Series B-1 funding. As part of the transaction, Nick Naclerio, Founding Partner of Illumina Ventures, will join Pattern’s Board of Directors.
Your screen does not meet the requirements for generating previews. Adjust your screen width to exactly 1920px before proceeding, otherwise you'll not be able to generate previews.
